API Supplier Delay
Consumables Cost +30%
New Contract Capacity
API Supplier Delay
Critical
Lonza notifies 6-week delay on mAb intermediate (LNZ-4821). Evaluate impact on
batch schedule, customer delivery commitments, and Q3 revenue targets across
Rituximab, Trastuzumab, and Adalimumab production lines.
Delay Duration
6 weeks
Products Affected
3 lines
Alt. Supplier Lead
10 weeks
Safety Stock
2.5 weeks
Impact Comparison
| Metric | Baseline | Scenario | Flow | Delta |
|---|---|---|---|---|
| On-time delivery | 96.2% | 71.8% | → | −24.4 pp |
| Batches at risk | 0 | 12 | → | +12 |
| Revenue impact | — | $8.4M | → | −$8.4M |
| Customer penalties | $0 | $1.2M | → | +$1.2M |
| Safety stock (weeks) | 2.5 | 0 | → | −2.5 |